Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
SkinBioTherapeutics ( (GB:SBTX) ) has issued an update.
SkinBioTherapeutics has disclosed that FRP Advisory is in the final stages of a forensic investigation, with the resulting report expected to be delivered to the board in the coming days. The company plans to review the findings with external advisers and then complete its HY26 results alongside restated unaudited FY25 figures, indicating that the investigation’s outcome will influence its financial reporting and governance approach, with implications for investors’ visibility on recent performance.
The timing of the report is likely to be closely watched by stakeholders, as the restatement of FY25 results and completion of HY26 accounts may affect confidence in the company’s financial controls and transparency. The board’s emphasis on regulatory and governance implications suggests that any conclusions from the investigation could shape how SkinBioTherapeutics positions itself in the market and addresses oversight expectations going forward.
Spark’s Take on SBTX Stock
According to Spark, TipRanks’ AI Analyst, SBTX is a Neutral.
The score is held back primarily by ongoing unprofitability and weak cash flows, despite strong revenue growth and a relatively conservative balance sheet. Technicals also remain bearish with the stock trading below major moving averages and negative MACD, while valuation is constrained by losses (negative P/E) and no dividend yield support.
To see Spark’s full report on SBTX stock, click here.
More about SkinBioTherapeutics
SkinBioTherapeutics is a UK-based life science company focused on skin health, built around its proprietary SkinBiotix platform originating from research at the University of Manchester. Its core business targets the skin healthcare market through pillars including cosmetic skincare and gut-skin axis food supplements, supported by partnerships such as Croda’s use of SkinBiotix as Zenakine and retail distribution of AxisBiotix products via Amazon and Superdrug. The group is also pursuing acquisitions in complementary skincare and cosmetic areas to expand distribution, geographic reach and manufacturing capabilities, following its listing on AIM in 2017.
Average Trading Volume: 6,110,150
Technical Sentiment Signal: Sell
Current Market Cap: £25.27M
Learn more about SBTX stock on TipRanks’ Stock Analysis page.